http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103417538-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61D7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4418 |
| filingDate | 2013-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103417538-B |
| titleOfInvention | Dedicated liquid medicine, dedicated tool and method for building animal model of parkinson's disease through intracerebral administration |
| abstract | The invention discloses dedicated liquid medicine, a dedicated tool and a method for building an animal model of parkinson's disease through intracerebral administration and belongs to a biomedical technology. The dedicated liquid medicine is solution which is prepared in such a manner that MPP<+> is dissolved into normal saline, wherein the concentration of the MMP<+> is 0.08-0.12 g/ml. The dedicated tool is a multi-point dosing needle tube which adopts the structure that one end of a hollow metal tube is closed and the other end of the metal tube is opened; substantia nigra dosing side holes and corpus striatum dosing side holes are formed in the side wall of the hollow metal tube. A path passing through both the substantia nigra and the corpus striatum in the cerebrum of a primate which is not a human is selected as a needle insertion path. Injection dosing is preformed on the substantia nigra and the corpus striatum through the multi-point dosing needle tube. The total dosage is 9-11 microlitres, and 12 hours after once dosing by needle insertion, the animal model of parkinson's disease is prepared successfully. According to the invention, the anatomical characteristics of the substantia nigra in the mesencephalon and corpus striatum nuclei, the own attributes of the chemical medicine (i.e. the liquid medicine) and the specific damage effects, to a dopaminergic neuron, of the chemical medicine are well utilized, so that an obvious hemi-parkinson's disease symptom occurs to the animal model immediately and can keep stable for a long time. Moreover, the basic physiological status of the animal model is good, and the individual difference is smaller. |
| priorityDate | 2013-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.